Alkermes Plc (ALKS)
44.99
+0.48
(+1.08%)
USD |
NASDAQ |
Jun 18, 16:00
44.92
-0.07
(-0.16%)
After-Hours: 20:00
Alkermes Research and Development Expense (Quarterly) : 101.64M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 101.64M |
| December 31, 2025 | 91.74M |
| September 30, 2025 | 80.34M |
| June 30, 2025 | 75.87M |
| March 31, 2025 | 70.42M |
| December 31, 2024 | 56.67M |
| September 30, 2024 | 58.49M |
| June 30, 2024 | 58.25M |
| March 31, 2024 | 66.21M |
| December 31, 2023 | 73.93M |
| September 30, 2023 | 94.74M |
| June 30, 2023 | 98.09M |
| March 31, 2023 | 61.47M |
| December 31, 2022 | 73.01M |
| September 30, 2022 | 97.33M |
| June 30, 2022 | 89.97M |
| March 31, 2022 | 93.15M |
| December 31, 2021 | 95.37M |
| September 30, 2021 | 115.51M |
| June 30, 2021 | 94.57M |
| March 31, 2021 | 88.87M |
| December 31, 2020 | 108.51M |
| September 30, 2020 | 90.88M |
| June 30, 2020 | 90.52M |
| March 31, 2020 | 89.58M |
| Date | Value |
|---|---|
| December 31, 2019 | 107.76M |
| September 30, 2019 | 104.07M |
| June 30, 2019 | 101.14M |
| March 31, 2019 | 99.27M |
| December 31, 2018 | 105.87M |
| September 30, 2018 | 98.26M |
| June 30, 2018 | 103.92M |
| March 31, 2018 | 105.05M |
| December 31, 2017 | 101.69M |
| September 30, 2017 | 101.71M |
| June 30, 2017 | 96.55M |
| March 31, 2017 | 102.44M |
| December 31, 2016 | 87.33M |
| September 30, 2016 | 97.34M |
| June 30, 2016 | 95.21M |
| March 31, 2016 | 99.37M |
| December 31, 2015 | 91.99M |
| September 30, 2015 | 91.06M |
| June 30, 2015 | 86.48M |
| March 31, 2015 | 68.68M |
| December 31, 2014 | 72.43M |
| September 30, 2014 | 76.16M |
| June 30, 2014 | 65.21M |
| March 31, 2014 | 52.14M |
| December 31, 2013 | 48.72M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amarin Corp. Plc | 4.020M |
| Prothena Corp. Plc | 12.63M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Catalyst Pharmaceuticals, Inc. | 2.661M |
| Inovio Pharmaceuticals, Inc. | 13.75M |